Dronabinol

Marinol, Syndros, Reduvo ve Adversa ticari isimleri altında da bilinen Uluslararası Tescilli Olmayan İsim dronabinol, farmasötik bağlamda delta-9-tetrahidrokanabinol molekülünün genel adıdır. İştah açıcı, antiemetik ve uyku apnesi giderici olarak endikasyonları vardır^[1] ve FDA tarafından yalnızca HIV/AIDS'in neden olduğu anoreksi ve kemoterapinin neden olduğu bulantı ve kusma için güvenli ve etkili olduğu onaylanmıştır.^[2]^[3]^[4]

Dronabinol, esrarda bulunan (-)-trans-Δ⁹- tetrahidrokanabinolün temel psikoaktif bileşen enantiyomer formudur.^[5] Dronabinol, başka herhangi bir tetrahidrokanabinol (THC) izomeri veya herhangi bir kannabidiol içermez.

Kaynakça

^ Dunn, Abbey; Braley, Tiffany J.; Pitt, Bertram; Shelgikar, Anita V. (2021). "New frontiers in pharmacologic obstructive sleep apnea treatment: A narrative review". Sleep Medicine Reviews. Elsevier BV. 57: 101473. doi:10.1016/j.smrv.2021.101473. ISSN 1087-0792. PMID 33853035. Initial rodent studies showed that injections of dronabinol, a synthetic form of delta-9-tetrahydrocannabinol, in the nodose ganglia suppressed serotonin induced reflex apneas and increased upper airway dilating muscle activity during sleep. Limited studies in humans with moderate-to-severe OSA have demonstrated significant reduction in AHI with dronabinol use. Birden fazla yazar-name-list parameters kullanıldı (yardım); Yazar |ad1= eksik |soyadı1= (yardım)
^ "Marinol (Dronabinol)" (PDF). US Food and Drug Administration. September 2004. 10 Şubat 2017 tarihinde kaynağından arşivlendi (PDF). Erişim tarihi: 14 Ocak 2018.
^ "Cannabis and Cannabinoids". National Cancer Institute. 24 Ekim 2011. 8 Mayıs 2015 tarihinde kaynağından arşivlendi. Erişim tarihi: 12 Ocak 2014.
^ "A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics". Cancer Chemotherapy and Pharmacology. 80 (3): 441-449. September 2017. doi:10.1007/s00280-017-3387-5. PMC 5573753 $2. PMID 28780725.
^ "List of psychotropic substances under international control". International Narcotics Control Board. 2 Ağustos 2019 tarihinde kaynağından arşivlendi. Erişim tarihi: 25 Nisan 2018. This international non-proprietary name refers to only one of the stereochemical variants of delta-9-tetrahydrocannabinol, namely (−)-trans-delta-9-tetrahydrocannabinol

[Schütz_2021-1] Dunn, Abbey; Braley, Tiffany J.; Pitt, Bertram; Shelgikar, Anita V. (2021). "New frontiers in pharmacologic obstructive sleep apnea treatment: A narrative review". Sleep Medicine Reviews. Elsevier BV. 57: 101473. doi:10.1016/j.smrv.2021.101473. ISSN 1087-0792. PMID 33853035. Initial rodent studies showed that injections of dronabinol, a synthetic form of delta-9-tetrahydrocannabinol, in the nodose ganglia suppressed serotonin induced reflex apneas and increased upper airway dilating muscle activity during sleep. Limited studies in humans with moderate-to-severe OSA have demonstrated significant reduction in AHI with dronabinol use. Birden fazla yazar-name-list parameters kullanıldı (yardım); Yazar |ad1= eksik |soyadı1= (yardım)

[fda-2] "Marinol (Dronabinol)" (PDF). US Food and Drug Administration. September 2004. 10 Şubat 2017 tarihinde kaynağından arşivlendi (PDF). Erişim tarihi: 14 Ocak 2018.

[3] "Cannabis and Cannabinoids". National Cancer Institute. 24 Ekim 2011. 8 Mayıs 2015 tarihinde kaynağından arşivlendi. Erişim tarihi: 12 Ocak 2014.

[4] "A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics". Cancer Chemotherapy and Pharmacology. 80 (3): 441-449. September 2017. doi:10.1007/s00280-017-3387-5. PMC 5573753 $2. PMID 28780725.

[5] "List of psychotropic substances under international control". International Narcotics Control Board. 2 Ağustos 2019 tarihinde kaynağından arşivlendi. Erişim tarihi: 25 Nisan 2018. This international non-proprietary name refers to only one of the stereochemical variants of delta-9-tetrahydrocannabinol, namely (−)-trans-delta-9-tetrahydrocannabinol

[1]

[2]

[3]

[4]

[5]